RUNX2 and ocular melanoma: However, more relevant to the need for a prompt assay within cGMP cell expansion timelines, after 1W-OM-PL treatment five biomarkers ALPL, COL1A2, DCN, ELN, RUNX2 represented the osteogenic “signature genes” significantly upregulated in all phenotypic contexts (Fig 5E, 1W Venn diagram).